U.S. CBD sales to reach $7B by 2023; Investments Soar

The passage of the U.S. Farm Bill has resulted in an influx of forward-thinking investors who are now spending millions of dollars on hemp and CBD companies.

According to the data included in a report conducted by MJBizDaily, Hemp companies raised over $230 million dollars in the first five months of 2019.

One top-performing company we are paying close attention to is Real Brands, Inc. (RLBD), a Hemp-Derived CBD Brand Building company.

By use of strategic marketing and effective brand building, Real Brands, Inc. (RLBD) is on track to becoming one of the leading legal Hemp-Derived CBD consumer products companies for each of its brands: CBD Pharmacy™, Omegahemp™, Humboldt Brands®, Hemp-Aid® and HempAid®.

According to Hemp Industry Daily market projections, the national market for hemp-derived CBD alone may reach as high as $7 billion by 2023.

Given this significant projected increase, this newly legal market is immeasurable for current and future investment opportunities.

Today we’re highlighting: Real Brands, Inc. (OTCPINK: RLBD), Insys Therapeutics Inc. (NASDAQ: INSY), Aurora Cannabis Inc. (NYSE: ACB), Canopy Growth Corporation (NYSE: CGC), Aphria Inc. (NYSE: APHA).

Real Brands, Inc. (OTCPINK: RLBD), (Market Cap: $10.450M; Share Price: $0.06), Real Brands, Inc. is a brand building company in the Legal Hemp and Cannabis industry. The Company is based in Pompano Beach, Florida. The Company’s acquisition strategy is for accretive acquisitions of trademarks, patents, other IP and related business opportunities that can be efficiently integrated into the Company’s infrastructure and financial capabilities so that the Company can benefit from the gross profit contribution from distribution, licensing, joint ventures and other opportunities.

Insys Therapeutics Inc. (NASDAQ: INSY), (Market Cap: $25.353M; Share Price: $0.29), Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist.

Aurora Cannabis Inc. (NYSE: ACB), (Market Cap: $7.246B; Share Price: $7.60), Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company’s products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. As of February 26, 2019, the company had operations in 24 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies.

Canopy Growth Corporation (NYSE: CGC), (Market Cap: $8.276B; Share Price: $41.87), Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada to investigate the efficacy of cannabinoids for the treatment of post-concussion neurological diseases in former NHL players; and partnership with Parent Action on Drugs.

Aphria Inc. (NYSE: APHA), (Market Cap: $1.577B; Share Price: $6.87), Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market.

As an up and coming leader in the cannabis space with a diverse CBD-based brand portfolio, Real Brands, Inc. (RLBD) provides its investors with the opportunity to continually capitalize on their investments as they aim to grow and expand by focusing on three core CBD Categories: smokables, edibles, and topical balms and lotions.


Legal Disclaimer:

 This article was written by Regal Consulting, LLC (“Regal Consulting”).  Regal Consulting has agreed to a three-month term consulting agreement with RLBD dated 8/31/18.  The agreement calls for $100,000 note issued to Regal Consulting, and 2,500,000 restricted 144 shares of RLBD for three months of service.  Regal has elected to convert $73,000 of principal of the $100,000 note into 2,761,872 Restricted 144 shares of RLBD. Regal Consulting has agreed to a twelve- month term consulting agreement with RLBD dated 1/4/2019.  The agreement calls for $10,000 in cash and 500,000 shares per month. All payments were made directly by Real Brands, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of.  Regal Consulting also paid one thousand dollars cash to to distribute this article.  Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice.  This article is based on public information and the opinions of Regal Consulting. RLBD was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein.  Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice. legal disclaimer/

 Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States